COVID-19 vaccines have recently been updated with the spike protein of SARS-Co-V-2 XBB.1.5 subvariant alone, but their immunogenicity in humans has yet to be fully evaluated and reported, particularly against emergent viruses that are rapidly expanding. We now report that administration of an updated monovalent mRNA vaccine (XBB.1.5 MV) to uninfected individuals boosted serum virus-neutralization antibodies significantly against not only XBB.1.5 (27.0-fold) and the currently dominant EG.5.1 (27.6-fold) but also key emergent viruses like HV.1, HK.3, JD.1.1, and JN.1 (13.3-to-27.4-fold). In individuals previously infected by an Omicron subvariant, serum neutralizing titers were boosted to highest levels (1,764-to-22,978) against all viral variants tested. While immunological imprinting was still evident with the updated vaccines, it was not nearly as severe as the previously authorized bivalent BA.5 vaccine. Our findings strongly support the official recommendation to widely apply the updated COVID-19 vaccines to further protect the public.
Preprint in bioRxiv (Nov. 27, 2023):
Buy OxyNorm liquid Online
ACXION FENTERMINA
$180.00 $150.00Add to cartacxion-fentermina 30mg
Alli Orlistat 60 mg
$200.00 $150.00Add to cartbuy Adderall 20 mg tablet
$200.00 $180.00Add to cartBuy arimidex for sale
buy Concerta online
buy demerol injection online
Buy Dilaudid Online
Buy Duromine online
Buy Ecstasy Online
buy Elite Assault Air Bike
$1,100.00Add to cartBuy Fentanyl Powder Online
buy Klonopin Clonazepam online
Buy Norco 10 mg-325 mg tablet
buy norco Norco 10 325 online